231 related articles for article (PubMed ID: 25483641)
1. TroVax in colorectal cancer.
Rowe J; Cen P
Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
[TBL] [Abstract][Full Text] [Related]
2. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses.
Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Melcher A; Nicholls J; Wassan H; Habib N; Anthoney A
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4487-94. PubMed ID: 17671134
[TBL] [Abstract][Full Text] [Related]
3. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a phase II trial.
Amato RJ; Shingler W; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
Clin Cancer Res; 2008 Nov; 14(22):7504-10. PubMed ID: 19010868
[TBL] [Abstract][Full Text] [Related]
4. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.
Harrop R; Drury N; Shingler W; Chikoti P; Redchenko I; Carroll MW; Kingsman SM; Naylor S; Griffiths R; Steven N; Hawkins RE
Cancer Immunol Immunother; 2008 Jul; 57(7):977-86. PubMed ID: 18060404
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
Amato RJ; Shingler W; Goonewardena M; de Belin J; Naylor S; Jac J; Willis J; Saxena S; Hernandez-McClain J; Harrop R
J Immunother; 2009 Sep; 32(7):765-72. PubMed ID: 19561532
[TBL] [Abstract][Full Text] [Related]
6. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2010 Feb; 10(2):281-7. PubMed ID: 20088718
[TBL] [Abstract][Full Text] [Related]
7. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I/II trial.
Harrop R; Connolly N; Redchenko I; Valle J; Saunders M; Ryan MG; Myers KA; Drury N; Kingsman SM; Hawkins RE; Carroll MW
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3416-24. PubMed ID: 16740766
[TBL] [Abstract][Full Text] [Related]
8. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
9. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial.
Amato RJ; Drury N; Naylor S; Jac J; Saxena S; Cao A; Hernandez-McClain J; Harrop R
J Immunother; 2008; 31(6):577-85. PubMed ID: 18528296
[TBL] [Abstract][Full Text] [Related]
11. TroVax(®) vaccine therapy for renal cell carcinoma.
Zhang RT; Bines SD; Ruby C; Kaufman HL
Immunotherapy; 2012 Jan; 4(1):27-42. PubMed ID: 22149999
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Kaufman HL; Taback B; Sherman W; Kim DW; Shingler WH; Moroziewicz D; DeRaffele G; Mitcham J; Carroll MW; Harrop R; Naylor S; Kim-Schulze S
J Transl Med; 2009 Jan; 7():2. PubMed ID: 19128501
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.
Hawkins RE; Macdermott C; Shablak A; Hamer C; Thistlethwaite F; Drury NL; Chikoti P; Shingler W; Naylor S; Harrop R
J Immunother; 2009 May; 32(4):424-9. PubMed ID: 19342962
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
Amato RJ; Hawkins RE; Kaufman HL; Thompson JA; Tomczak P; Szczylik C; McDonald M; Eastty S; Shingler WH; de Belin J; Goonewardena M; Naylor S; Harrop R
Clin Cancer Res; 2010 Nov; 16(22):5539-47. PubMed ID: 20881001
[TBL] [Abstract][Full Text] [Related]
15. 5T4-modified vaccinia ankara: progress in tumor-associated antigen-based immunotherapy.
Amato RJ
Expert Opin Biol Ther; 2007 Sep; 7(9):1463-9. PubMed ID: 17727334
[TBL] [Abstract][Full Text] [Related]
16. TroVax, a recombinant modified vaccinia Ankara virus encoding 5T4: lessons learned and future development.
Kim DW; Krishnamurthy V; Bines SD; Kaufman HL
Hum Vaccin; 2010 Oct; 6(10):784-91. PubMed ID: 20975327
[TBL] [Abstract][Full Text] [Related]
17. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
Harrop R; Shingler W; Kelleher M; de Belin J; Treasure P
J Immunother; 2010; 33(9):999-1005. PubMed ID: 20948436
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
Amato RJ; Stepankiw M
Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model.
Kim HS; Park HM; Park JS; Sohn HJ; Kim SG; Kim HJ; Oh ST; Kim TG
Vaccine; 2010 Nov; 28(49):7787-96. PubMed ID: 20883737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
